Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[225Ac]Ac-HTK03170 is a preclinical-stage, prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) labeled with the alpha-emitting radionuclide Actinium-225 ([225Ac]). Developed by BC Cancer and the University of British Columbia, the compound is designed for targeted alpha therapy (TAT) of advanced prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC). It consists of a PSMA-targeting small-molecule ligand conjugated to a DOTA chelator and incorporates a 4-(4-methoxyphenyl)butyric acid moiety as an albumin binder. This albumin-binding moiety extends the blood circulation half-life, enhancing tumor accumulation and therapeutic efficacy while minimizing off-target toxicity in salivary glands and kidneys. In preclinical models, [225Ac]Ac-HTK03170 has demonstrated high tumor uptake, favorable pharmacokinetics, and significant tumor regression.
| Indication | Highest phase | Status |
|---|---|---|
| metastatic castration-resistant prostate cancer (mCRPC) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Patent families, expiry dates and exclusivities are in the full profile.
Lead indication: metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [225Ac]Ac-HTK03170.
Work on [225Ac]Ac-HTK03170? Claim this page to correct or add information. Claim this page